97302 ⎘
Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen Internalization into the cell
Methods and compositions for treatment of Pompe disease
#1202Anti-CEACAM5 antibodies and uses thereof
#1203Therapeutic antibodies against ROR-1 protein and methods for use of same
#1204METHODS AND COMPOSITIONS FOR TREATMENT OF FORBES-CORI DISEASE
#1205Bispecific HER2 and HER3 antigen binding constructs
#1206mAB 2 anti-Met antibody
#1207Isoform specific anti-HER4 antibodies
#1208Anti-CLL-1 antibodies and immunoconjugates
#1209Human monoclonal antibodies to programmed death ligand 1 (PD-L1)
#1210Anti-DLL3 antibodies
#1211Methods for treating neoplasia
#1212Human antibody drug conjugates against tissue factor
#1213Site-specific glycoengineering of targeting moieties
#1214Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells
#1215SPECIFIC BINDING PROTEINS AND USES THEREOF
#1216Antigen binding proteins
#1217HER3 specific monoclonal antibodies for diagnostic and therapeutic use
#1218Human Antibody Fragments Against Chondroitin Sulfate Proteoglycan 4 (CSPG4)
#1219THERAPEUTIC AND DIAGNOSTIC TARGET FOR CANCER COMPRISING DLL3 BINDING REAGENTS
#1220Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
#1221Therapeutic use of anti-CD22 antibodies for inducing trogocytosis
#1222cKIT antibody drug conjugates
#1223Human monoclonal antibodies to fucosyl-GM1 and methods for using anti-fucosyl-GM1 antibodies
#1224Anti-GPC3 antibodies and immunoconjugates
#1225CD20-binding immunotoxins for inducing cellular internalization and methods using same
#1226Anti-B7-H4 antibodies and immunoconjugates
#1227Photosensitizing antibody-fluorophore conjugates
#1228Anti-DLL3 antibody drug conjugates
#1229Complex of bi-specific antibody and digoxigenin conjugated to a therapeutic or diagnostic agent
#1230Anti-TFPI Antibody Variants with Differential Binding Across pH Range For Improved Pharmacokinetics
#1231Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
#1232Methods of treating acute myeloid leukemia with antibodies to bone marrow stromal antigen 1
#1233HER1 antigen binding proteins binding to the beta-hairpin of HER1
#1234Anti-HER3 antibodies binding to the beta-hairpin of HER3
#1235Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells
#1236Siglec-9 binding agents
#1237Cell penetrating nucleolytic antibody based cancer therapy
#1238Anti-NTB-A antibodies and related compositions and methods
#1239Anti-PMEL17 antibodies and immunoconjugates
#1240Anti-DLL3 antibody
#1241Multispecific constructs
#1242Antibody constructs for CDH19 and CD3
#1243Monoclonal antibodies against HER2 epitope and methods of use thereof
#1244Intranuclear protein transduction through a nucleoside salvage pathway
#1245Composition of anti-ENDO180 antibodies and methods of use for the treatment of cancer and fibrotic diseases
#1246Human monoclonal antibodies to ganglioside GD2
#1247BCMA antigen binding proteins
#1248Anti-EphA2 antibodies and methods of use thereof
#1249Inert format
#1250Anti-CD324 monoclonal antibodies and uses thereof
#1251Anti-DLL3 antibody drug conjugates
#1252Anti-HER2 antibody and anti-c-Met/anti-HER2 bispecific antibodies comprising the same
#1253Antibodies targeting CDH19 for melanoma
#1254ANTIBODY DRUG CONJUGATES
#1255Anti-PTK7 antibody-drug conjugates
#1256Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
#1257Anti-human B7-H4 antibodies and their uses
#1258Antibody-SN-38 immunoconjugates with a CL2A linker
#1259Polypeptide vaccine
#1260ANTIGEN-BINDING MOLECULE FOR PROMOTING CLEARANCE FROM PLASMA OF ANTIGEN COMPRISING SUGER CHAIN RECEPTOR-BINDING DOMAIN
#1261Antibody-drug conjugate
#1262KIR3DL2 binding agents
#1263Use of endocytosis inhibitors and antibodies for cancer therapy
#1264CD33 binding agents
#1265Method for selective targeting and entry of bacterial toxins to cells
#1266CD19 binding agents and uses thereof
#1267Antibodies reactive with B7-H3, immunologically active fragments thereof and uses thereof
#1268Polypeptides capable of cellular internalization
#1269Antibodies to CD70
#1270Anti-IL-13 receptor alpha 2 antibodies and antibody-drug conjugates
#1271Antibodies reactive with B7-H3, immunologically active fragments thereof and uses thereof
#1272ANTI-MESOTHELIN ANTIBODIES AND USES THEREOF
#1273CD20-binding proteins comprising Shiga toxin A subunit effector regions for inducing cellular internalization and methods using same
#1274Human monoclonal antibodies against CD25
#1275Anti-EGFRvIII antibodies and uses thereof
#1276Immunoparticles and methods of generating and using same
#1277Internalizing ErbB2 antibodies
#1278Anti-EGFR/anti-HER2 bispecific antibodies with anti-EGFR DARPins
#1279Fc variants with increased affinity for FcyRIIc
#1280KIR3DL2 binding agents
#1281Immunogenic compositions comprising progastrin and uses thereof
#1282Methods and compositions for treatment of myotubular myopathy using chimeric polypeptides comprising myotubularin 1(MTM1) polypeptides
#1283CD27L antigen binding proteins
#1284THERAPEUTIC AND DIAGNOSTIC TARGET
#1285Anti-ILT5 antibodies and ILT5-binding antibody fragments
#1286Blood-brain barrier targeting antibodies
#1287Anti-CD22 anti-idiotypic antibodies and uses thereof
#1288Multifunctional antibodies binding to EGFR and MET
#1289Dimeric protein with triple mutations
#1290Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
#1291Antibodies against amyloid beta 4 with glycosylation in the variable region
#1292CYSTEINE ENGINEERED ANTI-TENB2 ANTIBODIES AND ANTIBODY DRUG CONJUGATES
#1293Fixed dosage regimens for anti-type I interferon receptor (IFNAR) antibodies
#1294Antibody against transporter and use thereof
#1295Anti-αβantibodies
#1296CARRIER FOR INTRACELLULAR DELIVERY OF FUNCTIONAL PROTEIN
#1297TLR3 binding agents
#1298GLYCOENGINEERED BINDING PROTEIN COMPOSITIONS
#1299Targeted protein replacement for the treatment of lysosomal storage disorders
#1300Disease therapy by inducing immune response to Trop-2 expressing cells
#1301Anti-EFNA4 antibody-drug conjugates
#1302Anti-tumor endothelial marker-1 (TEM1) antibody variants and uses thereof
#1303Anti-LAMP5 antibody and utilization thereof
#1304Humanized anti-epiregulin antibody, and cancer therapeutic agent comprising said antibody as active ingredient
#1305Compositions and methods for the diagnosis and treatment of tumor
#1306Antibodies that specifically bind to TIM3
#1307Anti-CD22 antibodies
#1308Humanized pan-HER antibody compositions
#1309Use of an anti-Ang2 antibody
#1310Optimized Fc variants and methods for their generation
#1311Internalizing human monoclonal antibodies targeting prostate cancer cells in situ
#1312Anti-mesothelin antibodies and immunoconjugates
#1313GITR antigen binding proteins and methods of use thereof
#1314Antibodies to tumor endothelial marker 7R
#1315Antisense conjugates for decreasing expression of DMPK
#1316Anti-PRLR antibodies and methods for killing PRLR-expressing cells
#1317Anti-PRLR antibodies and methods for killing PRLR-expressing cells
#1318Nucleic acids encoding human antibodies to sialyl-lewis
#1319Binding molecules with antitumoral activity
#1320Anti-Siglec-15 antibodies and uses thereof
#1321Antigen binding protein and its use as addressing product for the treatment of cancer
#1322Methods of inhibiting solid tumor growth by administering GPR49 antibodies
#1323Methods and compositions for inhibiting CD32B expressing cells
#1324Methods and compositions for inhibiting CD32b expressing cells
#1325Method of blocking vascular leakage using an anti-ANG2 antibody
#1326Anti-Ang2 antibody
#1327Bispecific chimeric proteins comprising DARPins
#1328Compositions and methods for the diagnosis and treatment of tumor
#1329Anti SEZ6 antibodies and methods of use
#1330Single domain antibodies as inhibitors of PCSK9
#1331Optimized Fc variants
#1332Vaccines against antigens involved in therapy resistance and methods of using same
#1333Anti-DLL3 antibody drug conjugates for treating cancer
#1334Anti-DLL3 antibody drug conjugates
#1335PSCA: PROSTATE STEM CELL ANTIGEN AND USES THEREOF
#1336Anti-DLL3 antibodies
#1337Methods of detection, diagnosis, and monitoring using anti-DLL3 antibodies
#1338Anti-DLL3 antibody drug conjugates and methods of use
#1339Binding molecules specific for HER3 and uses thereof
#1340Method of target membrane protein depletion
#1341Anti-B7-H4 antibodies and their uses
#1342Tissue specific expression of antibodies in chickens
#1343B7-H3L cell surface antigen and antibodies that bind thereto
#1344Antibodies that bind OV064 and methods of use therefor
#1345Antibodies reactive with B7-H3 and uses thereof
#1346Multivalent antibodies and uses therefor
#1347Anti-B7-H4 antibodies and immunoconjugates
#1348Targeted carriers for drug delivery across the gastrointestinal epithelium
#1349Sur-binding proteins against ERBB3
#1350Anti-ErbB3 antibodies and uses thereof
#1351Methods of modulating inflammasome activity to treat inflammatory conditions
#1352Antibodies binding to an intracellular PRL-1 or PRL-3 polypeptide
#1353Anti-TFPI antibody variants with differential binding across PH range for improved pharmacokinetics
#1354Antibody drug conjugates
#1355Internalizing human monoclonal antibodies targeting prostate and other cancer cells
#1356Therapeutic uses for VEGFR1 antibodies
#1357Methods of blocking cancer stem cell growth
#1358Specific binding proteins and uses thereof
#1359Anti-DDR1 antibody having anti-tumor activity
#1360Antibody variants and uses thereof
#1361Frizzled 2 as a target for therapeutic antibodies in the treatment of cancer
#1362Antibodies to CD70
#1363Peptide or arrangement of peptides forming a epitope binding site
#1364Antibody-mediated transduction of heat shock proteins into living cells
#1365Antibody-SN-38 immunoconjugates with a CL2A linker
#1366Rapid clearance of antigen complexes using novel antibodies
#1367Compositions and methods to enhance the immune system
#1368Anti-PDGFR-beta antibodies and uses thereof
#1369Therapeutic and diagnostic target
#1370Monoclonal antibodies against Glypican-3
#1371HER3 antibodies binding to the beta-hairpin of HER3
#1372Anti-HER3/HER4 antibodies binding to the beta-hairpin of HER3 and the beta-hairpin of HER4
#1373Generation of anti-FN14 monoclonal antibodies by ex-vivo accelerated antibody evolution
#1374Antibody specific for CD22 and methods of use thereof
#1375BCMA antigen binding proteins
#1376Platelet derived growth factor receptor supports cytomegalovirus infectivity
#1377Monoclonal antibodies and single chain antibody fragments against cell-surface prostate specific membrane antigen
#1378EPHB3-specific antibody and uses thereof
#1379Antibodies to CD70
#1380Antigen binding protein and its use as addressing product for the treatment of cancer
#1381Antibodies to CD70
#1382Small molecule conjugates for intracellular delivery of biologically active compounds
#1383Small molecule conjugates for intracellular delivery of nucleic acids
#1384TCR mimic antibodies as vascular targeting tools
#1385Human monoclonal antibodies to O8E
#1386Anti-mesothelin antibodies
#1387Antigen presenting cell targeted anti-viral vaccines
#1388Anti-CD22 antibodies and immunoconjugates and methods of use
#1389Photosensitizing antibody-fluorophore conjugates
#1390Mammalian receptors as targets for antibody and active vaccination therapy against mold infections
#1391Anti-human HER3 antibodies and uses thereof
#1392Antibodies against tropomyosin-related kinase B receptors
#1393HERV-K antigens, antibodies, and methods
#1394Modulators and methods of use
#1395Optimized antibodies that target CD19
#1396Compositions and methods for the diagnosis and treatment of tumor
#1397Compositions and methods for the diagnosis and treatment of tumor
#1398Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of B-cell malignancies symptoms
#1399Antibodies or fragments thereof directed against a epitope of IsaA or IsaB
#1400Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody
#1401Anti-kit antibodies
#1402Human IgM antibodies, and diagnostic and therapeutic uses thereof particularly in the central nervous system
#1403Method of treating hypertension disorder and a pharmaceutical agent
#1404Anti-kit antibodies
#1405Anti-CD19 antibodies and uses in B cell disorders
#1406Cell-penetrating anti-DNA antibodies and uses thereof inhibit DNA repair
#1407Targeting poly-gamma-glutamic acid to treat and related infections
#1408Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
#1409Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity
#1410Human antibodies and antibody-drug conjugates against CD74
#1411Fully human antibodies to BTLA
#1412Antibody for 3′-isoLM1 and 3′,6′-iso-LD1 gangliosides
#1413Antibody conjugates against variant NFKBIB and uses thereof
#1414Internalizing erbB2 antibodies
#1415Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
#1416LOX and LOXL2 inhibitors and uses thereof
#1417Molecules and methods for modulating TMEM16A activities
#1418Anti-CDH3 antibody having high internalization capacity
#1419Methods and compositions for inhibiting CD32B expressing cells
#1420Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
#1421Modulators and methods of use
#1422Alpha emitting constructs and uses thereof
#1423Anti-PMEL17 antibodies and immunoconjugates
#1424Dock-and-Lock (DNL) Complexes for delivery of interference RNA
#1425Anti-FGFR3 antibodies and methods using same
#1426Therapeutic antibodies against ROR-1 protein and methods for use of same
#1427Antibodies to bone marrow stromal antigen 1
#1428Specific binding proteins and uses thereof
#1429Targeting intracellular target-binding determinants with intracellular antibodies
#1430Compositions and methods for treatment of drug resistant multiple myeloma
#1431Anti-ROR1 antibodies and methods of use for treatment of cancer
#1432Human antibodies that bind CD22 and uses thereof
#1433ErbB3 binding antibody
#1434Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile
#1435Anti-tumor antigen antibodies and methods of use
#1436Anti-C-met antibody and methods of use thereof
#1437In vivo polynucleotide delivery conjugates having enzyme sensitive linkages
#1438Monoclonal antibodies against HER2
#1439Anti-human epidermal growth factor receptor antibody and uses thereof
#1440Antibodies to MUC16 and methods of use thereof
#1441Monoclonal antibodies against HER2 epitope
#1442Anti-human transferrin receptor antibody and uses thereof
#1443Antibodies to the B12-transcobalamin receptor
#1444Antigen binding proteins
#1445Optimized Fc variants and methods for their generation
#1446Optimized FC variants and methods for their generation
#1447Compositions and methods for the treatment of tumor of hematopoietic origin
#1448Antibodies reactive with B7-H3, immunologically active fragments thereof and uses thereof
#1449Human monoclonal antibodies to Fucosyl-GM1 and methods for using anti-Fucosyl-GM1 antibodies
#1450Therapeutic use of anti-CD22 antibodies for inducing trogocytosis
#1451Methods, compositions and kits relating to chitnases and chitnase-like molecules and inflammation disease
#1452Biological materials related to HER3
#1453Pulmonary administration of immunoglobulin single variable domains and constructs thereof
#1454Humanized anti-CD19 antibodies
#1455Human antibody drug conjugates against tissue factor
#1456Antibodies that bind human dendritic and epithelial cell 205 (DEC-205)
#1457Compositions and methods for treating neurological disorders
#1458Multivalent antibody complexes targeting IGF-1R show potent toxicity against solid tumors
#1459Anti-ErbB3 antibodies and uses thereof
#1460Anti-HLA-DR Antibodies Suppress Allogeneic and Xenogeneic Immune Responses to Organ Transplants
#1461CD27L antigen binding proteins
#14621B20 PCSK9 antagonists
#1463Antibodies to tumor endothelial marker 7R
#1464Optimized fc variants and methods for their generation
#1465Method for the treatment of T cell mediated conditions by depletion of ICOS-positive cells in vivo
#1466Antibodies that bind OV064 and methods of use therefor
#1467Anti-FGFR3 antibodies and methods using same
#1468IMMUNO-BASED BOTULINUM TOXIN SEROTYPE A ACTIVITY ASSAYS
#1469Antibodies Against A Cancer-Associated Epitope of Variant HNRNPG and Uses Thereof
#1470Heterodimeric antibody Fc-containing proteins and methods for production thereof
#1471Adenocarcinoma specific antibody SAM-6, and uses thereof
#1472Anti-ILT5 antibodies and ILT5-binding antibody fragments
#1473Human antibodies that bind mesothelin, and uses thereof
#1474Human antibodies that bind mesothelin, and uses thereof
#1475Human antibodies that bind mesothelin, and uses thereof
#1476Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
#1477Tissue specific expression of antibodies in chickens
#1478Antibodies that specifically bind to TIM3
#1479Antibodies directed to GPNMB and uses thereof
#1480OVR115 ANTIBODY COMPOSITIONS AND METHODS OF USE
#1481Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
#1482Anti-CD22 antibodies and immunoconjugates and methods of use
#1483Anti-DLL3 antibody
#1484Drug delivery of temozolomide for systemic based treatment of cancer
#1485Anti-Rhesus D Recombinant Polyclonal Antibody and Methods of Manufacture
#1486INHIBITION OF FcyR-MEDIATED PHAGOCYTOSIS WITH REDUCED IMMUNOGLOBULIN PREPARATIONS
#1487Methods and compositions for inhibiting CD32B expressing cells
#1488ANTI-C4.4A ANTIBODIES AND USES THEREOF
#1489CRYSTAL STRUCTURES AND METHODS USING SAME
#1490Antibodies that bind human dendritic and epithelial cell 205 (DEC-205)
#1491Molecules and methods for modulating TMEM16A activities
#1492Targeting poly-gama-glutamic acid to treat and related infections
#1493ANTI-MN ANTIBODIES AND METHODS OF USING SAME
#14941D05 PCSK9 antagonists
#1495CD19 binding agents and uses thereof
#1496Anti-TEM1 antibodies and uses thereof
#1497Antibodies reactive with B7-H3 and uses thereof
#1498c-Kit antibodies and uses thereof
#1499Bi-specific digoxigenin binding antibodies
#1500ROR1 as Therapeutic and Diagnostic Target